Avatrombopag 是一种新型口服血小板生成素 (TPO) 受体激动剂，可激活 TPO 受体并增加巨核细胞增殖/分化和血小板生成。
产品描述
Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.
体内活性
Avatrombopag is treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure[1].
Cas No.
570406-98-3
分子式
C29H34Cl2N6O3S2
分子量
649.65
别名
1-[3-氯-5-[[[4-(4-氯-2-噻吩基)-5-(4-环己基-1-哌嗪基)-2-噻唑基]氨基]羰基]-2-吡啶基]-4-哌啶羧酸;E5501;AKR-501;YM477
储存和溶解度
DMSO:32 mg/mL (49.26 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
